|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding显示文摘 | Guillaume Paré Niclas Eriksson Thorsten Lehr Stuart Connolly John Eikelboom Michael D. Ezekowitz Tomas Axelsson Sebastian Haertter Jonas Oldgren Paul Reilly Agneta Siegbahn Ann-Christine Syvanen Claes Wadelius Mia Wadelius Heike Zimdahl-Gelling Salim Yusu | 2013 | Circulation2013，，13： | 2 |
| 2 | Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity 显示文摘 | van Ryn J Stangier J Haertter S | 2010 | Thromb Haemost2010，103，： | 1 |
| 3 | Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity显示文摘 | Van Ryn J Stangier J Haertter S | 2010 | Thromb Haemost2010，103，6： | 1 |
| 4 | Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity显示文摘 | VAN RYN J STANGIER J HAERTTER S | 2010 | ThrombHaemost2010，103，6： | 1 |
| 5 | The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients:the RE-LY Trial(Randomized Evaluation of Long-Term Anticoagulation Therapy)显示文摘 | Reilly PA Lehr T Haertter S | 2014 | J Am Coll Cardiol2014，63，4： | 1 |
| 6 | Dabigatran etexilate--a novel, reversi- ble, oral direct thrombin inhibitor:interpretation of coagulation assays and rever- sal of anticoagulant activity 显示文摘 | van Ryn J Stangier J Haertter S | 2010 | Thrornb Haemost2010，103，6： | 1 |
| 7 | Dabigatran etexilate-a novel,reversible,oral direct thrombin inhibitor:interpretation of coagulation assays and reversal of anticoagulant activity显示文摘 | VAN R J STANGIER J HAERTTER S | 2010 | Thromb Haemost2010，103，6： | 1 |
| 8 | Dabigatranetexilate-a novel, reversible, oral direct thrombin inhi-bitor :interpretation of coagulation assays andreversal ofanticoagulant activity 显示文摘 | van Ryn J Stangier J Haertter S | 2010 | Thromb Haemost2010，103，6： | 1 |
| 9 | Dabigatran etexilate --a novel, reversi- ble, oral direct thrombin inhibitor: interpretation of coagulation assays and re- versal of anticoagulant activity显示文摘 | an Ryn J Strangier J Haertter S | 2010 | Thromb Haemost2010，103，： | 1 |
| 10 | Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity 显示文摘 | van Ryn J Stangier J Haertter S | 2010 | Thromb Haemost2010，103，6： | 1 |
| 11 | The effect of dabigula-an plasma concentra- tions and patient characteristics on the frequency of isehemic stroke and major bleeding in atrial fibrillation patients : the RE-LY Trial ( Randomized Evaluation of Long-Term Anticoagulafian Therapy) 显示文摘 | Rellly PA Lehr T Haertter S | 2014 | J Am Coil Cardiol2014，63，4： | 1 |
| 12 | The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy) 显示文摘 | Reilly P A Lehr T Haertter S | 2014 | Journal of the American College of Cardiology2014，63，4： | 1 |
| 13 | Dabigatran etexilate a novel, re- versible, oral direct thrombin inhibitor : interpretation of coagulation assays and reversal of anticoagulant activity 显示文摘 | van Ryn J Stangier J Haertter S | 2010 | Thromb Haemost2010，103，6： | 1 |
| 14 | Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation:a pharmacokinetic justification显示文摘 | Clemens A Haertter S Friedman J | 2012 | Curr Med Res Opin2012，28，2： | 1 |
| 15 | Dabigatran etexilate in atrial fibrillation patients with severe renal impairment:dose identification using pharmacokinetic modeling and simulation显示文摘 | Lehr T Haertter S Liesenfeld KH | 2012 | J Clin Pharmacol2012，52，9： | 1 |
| 16 | The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic strokeand major bleeding in atrial fibrillation patients:the RE-LY Trial(Randomized Evaluation of Long-Term Anticoagulation Therapy)显示文摘 | REILLY P A LEHR T HAERTTER S | 2014 | JAm Coll Cardiol2014，63，： | 1 |
| 17 | Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity 显示文摘 | van Ryn J Stangier J Haertter S | 2010 | Thromb Haemost2010，103，6： | 1 |
| 18 | Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity显示文摘 | van-Ryn J Stangier J Haertter S | 2010 | Thromb Haemost2010，103，6： | 1 |
| 19 | Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity 显示文摘 | Van RJ Stangier J Haertter S | 2010 | Thromb Haemost2010，103，6： | 1 |
| 20 | Dabiga- tran etexilate---a novel, reversible, oral direct thrombin in- hibitor: interpretation of coagulation assays and reversal of anticoagulant activity显示文摘 | VAN RYN J STANGIER J HAERTTER S | 2010 | Thromb Haemost2010，103，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员